Introduction
============

Urinary tract infections (UTIs), especially those limited to the lower urinary tract, are commonly reported in young febrile children. Especially in children with vesico-ureteral reflux (VUR), UTI recurrence has been reported to be associated with development of pyelonephritis and renal scarring. These sequelae cause major concern for potential development of hypertension, chronic kidney disease, and possible growth impairment \[[@b1-krcp-38-441]--[@b3-krcp-38-441]\]. Thus, prevention of recurrent UTIs in children may help prevent subsequent chronic kidney damage.

The incidence of UTIs in children varies with age, sex, circumcision status in males, race, ethnicity, and geographic location. In infants less than 1 year old, boys (2.7% to 3.7%) are more prone to UTIs than girls (0.7% to 2%). The sex-based difference in incidence is even more pronounced during the first 2 to 6 months, when uncircumcised boys are at 10- to 20-fold higher risk of developing a UTI. However, this trend is reversed for children in the age group of 1 to 7 years, when girls (0.9% to 8%) are more prone to UTIs than boys (0.2% to 2%) \[[@b4-krcp-38-441]--[@b7-krcp-38-441]\]. This reversal is attributed to shorter urethral length in girls, which enhances the chance for an ascending infection from the urethra to the bladder and upper urinary system \[[@b4-krcp-38-441]\].

Most UTIs in children are caused by *Escherichia coli* (detected in approximately 80% of cases), a microorganism that adheres to the inner lining of the urinary tract by its fimbriae (pili) and subsequently enters epithelial cells \[[@b4-krcp-38-441],[@b8-krcp-38-441]\]. Other microorganisms that are generally encountered in children include *Klebsiella pneumoniae*, *Enterobacter* spp., *Enterococcus* spp., *Staphylococcus* spp., and *Pseudomonas aeruginosa*. These microorganisms are mostly found in recurrent UTIs and are more likely to cause renal scarring later in life compared to *E. coli* \[[@b8-krcp-38-441]--[@b10-krcp-38-441]\].

A retrospective study involving 262 children below one year of age with a first episode UTI revealed that about one third of the children had recurrent UTIs within 6 months of the primary infection. Concurrent Grade 3 to 5 VUR was identified as the most significant risk factor for recurrent UTI, and routine monthly follow-up was recommended for such children \[[@b11-krcp-38-441]\]. The risk of renal scarring is reported to increase with increased number of recurrent UTIs and higher VUR grade \[[@b12-krcp-38-441]\]. The National Institute for Health and Clinical Excellence summarized various predisposing factors for the development of recurrent UTIs and ensuing renal scarring. The factors include first UTI at 6 months or less, concurrent VUR (higher grades), male infant under 3 months or girl infant over 3 months, uncircumcised boy, anatomic abnormality in genitourinary tract, bladder instability, infrequent or dysfunctional voiding, lack of breastfeeding, fecal and perineal colonization, poor fluid intake, and constipation \[[@b13-krcp-38-441]\].

Continuous antibiotic prophylaxis (CAP) was initially introduced for prevention of recurrent UTIs without any controlled clinical study results \[[@b14-krcp-38-441],[@b15-krcp-38-441]\]. Based on results of clinical studies, CAP was later proposed to avoid recurrent UTIs in children with an anatomical abnormality in the urinary system, prenatal hydronephrosis, and/or VUR. The practice was recommended by some treatment guidelines, although it was based on limited data \[[@b13-krcp-38-441]\]. Over time, the practice of CAP was further extended for preventing UTIs in children without complications such as VUR, hydronephrosis, or anatomical abnormalities. CAP overuse has started a debate about the usefulness of CAP in preventing renal scarring, which is the real concern of recurrent UTIs. Currently, available cumulative clinical evidence indicates that CAP confers negligible efficacy for prevention of renal scarring, the long-term sequelae and major concern of recurrent UTIs \[[@b16-krcp-38-441]--[@b18-krcp-38-441]\]. Additionally, over-prescription of CAP is linked with a higher incidence of acquired antibiotic resistance, increased medical and economic burden, disruption of natural bacterial flora, and unknown long-term adverse effects \[[@b16-krcp-38-441],[@b19-krcp-38-441],[@b20-krcp-38-441]\]. Unfortunately, controversies in the literature and inconsistencies in guidelines for the utilization of CAP to prevent subsequent UTIs have led to diverse medical practices. The current study presents a review of various studies published between January 2000 and April 2019 and evaluates CAP use in children for prevention of recurrent UTIs.

Literature review
=================

The MEDLINE electronic database was searched for studies published between January 2000 to April 2019 using the following search terms: 'urinary tract infection' AND 'antimicrobial or antibiotic prophylaxis' AND 'children' OR 'pediatrics'. For the purpose of this review, 'continuous antibiotic prophylaxis' was defined as daily antibiotic dosing for at least 6 months. Only studies written in English were included. Randomized clinical trials (RCTs), original research articles, guidelines, systematic reviews, meta-analyses, and reviews describing antibiotic prophylaxis for UTIs were included. Duplicate studies, studies carried out on adults (\> 18 years), and case reports were excluded. Abstracts for all filtered publications were reviewed by the authors of this study to remove irrelevant publications. Full-text PDFs for all relevant publications were retrieved and reviewed by the authors. A total of 34 RCTs, 9 systematic reviews, and 3 guidelines describing antibiotic prophylaxis for UTIs were reviewed ([Fig. 1](#f1-krcp-38-441){ref-type="fig"}). Additional references were identified from the bibliography of selected relevant publications. Information from related articles was organized into several key areas identified by consensus among the authors.

A forest plot was constructed from included RCTs. The frequency of UTI events in the antibiotic prophylaxis group versus those with no prophylaxis were extracted from each individual study. Effect estimates were computed as risk ratios (RRs) and their respective 95% confidence intervals (CIs). Statistical heterogeneity between studies was assessed using a I^2^ test, where heterogeneity was considered significant at I^2^ \> 50%. A random-effects model was applied when there was significant heterogeneity. Statistical analysis was performed using RevMan software 5.3.5.

Microbial resistance in UTIs
============================

The major issue with overuse of antibiotic prophylaxis for preventing possible future recurrent infections is the advent of antibiotic-resistant strains of microorganisms. The proportion of such antibiotic-resistant strains has progressively increased in recent years, even in children without any significant health-related risk factors, due to overuse of broad-spectrum antibiotics to prevent future infections \[[@b19-krcp-38-441],[@b20-krcp-38-441]\]. The emergence of multidrug-resistant bacteria such as extended-spectrum beta-lactamase (ESBL) producing *E. coli* has made management of UTIs even more challenging for medical practitioners, microbiologists, and pharmacists. Genetic information needed for production of ESBL enzymes can be transferred between bacterial strains via plasmids. ESBL-producing bacteria can hydrolyze various broad-spectrum antibiotics, such as penicillins, cephalosporins, and mono-bactams, which become ineffective against such bacterial strains. This leaves very few options for treatment.

Various clinical research studies have evaluated the efficacy of CAP for prevention of recurrent UTIs in children. Studies found that CAP has limited efficacy and is associated with an increased risk of infections with antibiotic-resistant bacterial strains \[[@b21-krcp-38-441]--[@b23-krcp-38-441]\]. Several risk factors have been linked with the emergence of antibiotic-resistant bacterial strains in children with recurrent UTIs. The prevalence of antibiotic-resistant *E. coli* and other bacterial strains was significantly higher in children up to 2 years old compared with older children and adolescents. Moreover, the average antibiotic-resistance rate was significantly higher in boys than in girls for both inpatient and outpatient settings \[[@b24-krcp-38-441],[@b25-krcp-38-441]\]. According to a surveillance study carried out on urinary tract isolates of *E. coli*, children receiving CAP had a 23-fold increased risk of infection with *E. coli* resistant to trimethoprim-sulfamethoxazole (TMP-SMX), the representative "first-line" agent used for CAP \[[@b26-krcp-38-441]\]. Similarly, results from other studies demonstrated the high emergence rate of antibiotic-resistant bacteria in children receiving CAP. The chance of infection with such antibiotic-resistant bacterial strains is particularly high in children who received CAP in the previous 6 months \[[@b26-krcp-38-441]--[@b30-krcp-38-441]\]. Less time for previous antibiotic exposure is associated with increased risk of developing antibiotic resistance. A group of researchers reported that exposure to amoxicillin with-in 30 days of a UTI was related with resistance to ampicillin, amoxicillin, and amoxicillin-clavulanate; exposure to amoxicillin within 30 to 60 days of a UTI was linked with resistance to ampicillin; exposure to amoxicillin within \> 60 days of a UTI was not associated with resistance to ampicillin \[[@b30-krcp-38-441]\]. Pre-existing neurological diseases, recent hospitalization (within 1 month), concurrent high-grade (greater than or equal to 3) VUR, and previous *Klebsiella* spp. infection were also identified as potential risk factors for development of UTIs caused by ESBL producing multidrug-resistant bacterial strains \[[@b31-krcp-38-441],[@b32-krcp-38-441]\].

Breakthrough UTIs in children who were on CAP or who received CAP just before the UTI generally involve microorganisms that are resistant to both the antibiotic used for CAP as well as multiple other antibiotics, rendering them difficult to treat. The emergence of ESBL-producing bacteria is related to use of broad-spectrum antibiotics such as third-generation cephalosporins, amoxicillin, and quinolones for CAP, while the use of narrow-spectrum antibiotics such as TMP-SMX and nitrofurantoin for CAP are less likely to cause infection with antibiotic-resistant strains \[[@b26-krcp-38-441]--[@b28-krcp-38-441],[@b33-krcp-38-441]--[@b35-krcp-38-441]\]. Thus, broad-spectrum antibiotics should be avoided or limited for CAP in children with initial UTIs and concurrent anatomic abnormality in UTI. Cephalosporins, especially first-generation cephalosporins, are strong inducers of AmpC β-lactamases. Previous reports indicate that use of cephalosporin as a prophylactic antibiotic in children with VUR is strongly linked with the development of infection with ESBL-producing bacteria. Therefore, antibiotics should be judiciously prescribed after considering their potential to cause secondary infections with resistant bacterial strains.

A recent meta-analysis compared 1,299 children with recurrent UTIs and history of VUR who were receiving CAP to those receiving placebo/no treatment. Results conveyed that children on CAP were more likely to develop multidrug-resistant infections than those on placebo/no treatment (33% versus 6%, *P* value \< 0.001; odds ratio \[OR\], 6.4; 95% CI, 2.7--15.6). One in 21 cases of children on CAP developed a multidrug-resistant infection. Children on CAP were significantly more likely to receive broad-spectrum antibiotics to resolve their recurrent UTI compared to children not on CAP (68% versus 49%, *P* value = 0.004). Also, multidrug-resistant infections were related to longer hospitalization and a higher rate of developing pyelonephritis. A group of researchers from California reported that the total rate of hospitalization for pyelonephritis surged by more than 80% between 1985 and 2005. This period also showed a 5-times increase in cases of multidrug-resistant infections. Thus, increased incidence of multidrug-resistant infections is proposed to play a role in the higher rate of hospitalization due to pyelonephritis \[[@b35-krcp-38-441]\].

To understand the dynamics of multidrug-resistant infections, it is important to study the geographic distribution of such infections over time. For this purpose, studies carried out in different countries were reviewed, including the United States, Canada, Belgium, France, Belgium, Turkey, Iran, Jordan, Korea, and Taiwan ([Table 1](#t1-krcp-38-441){ref-type="table"}) \[[@b27-krcp-38-441]--[@b29-krcp-38-441],[@b36-krcp-38-441]--[@b43-krcp-38-441]\]. The patterns of multidrug resistance in pathogens causing UTIs among children of various age groups, sexes, and clinical conditions were studied \[[@b27-krcp-38-441]--[@b45-krcp-38-441]\]. Consistently across all geographic locations, recurrent UTIs caused by *E. coli* were considerably less common in children who received CAP compared with first episode UTIs. The overall incidence of UTIs and UTIs caused by ESBL-producing *E. coli*/other bacterial strains increased significantly over time in all geographic locations and all subgroups of pediatric patients. However, the antibiotic susceptibility pattern for UTIs across different geographic locations is slightly different. In Asia, studies of children with confirmed UTIs reported an ampicillin resistance rate of 66% to 82%, whereas TMP-SMX resistance was 50% to 62% \[[@b31-krcp-38-441],[@b36-krcp-38-441],[@b40-krcp-38-441]--[@b42-krcp-38-441]\]. In the United States, most samples collected from children with suspected/confirmed UTI were sensitive to a first-generation cephalosporin, amoxicillin-clavulanate, and nitrofurantoin \[[@b43-krcp-38-441],[@b44-krcp-38-441]\]. Efficient antibiotic stewardship and sensible selection of antibiotics based on identification of the causative organism (whether multidrugresistant or not) and on geographic location/local guidelines is paramount for treating UTIs in children whether or not they are receiving antibiotic prophylaxis.

Controversy regarding CAP
=========================

Current literature suggests that controversy remains among results obtained from different studies on the efficacy of CAP in preventing recurrent UTIs in children. Some studies suggest that CAP prevents recurrent UTIs in children who are prone to recurrent UTIs. Conversely, other studies suggest no or minimal efficacy of CAP. Another issue associated with these studies was use of variable standards, which makes it difficult to generalize the obtained results to the normal population. For example, most studies involved a non-stringent definition of UTI, an inconsistent/not standardized specimen collection method for identification of causative pathogens, inconsistent time intervals for urine analysis and surveillance of urinary cultures, inclusion of only children with lower grade VUR, and exclusion of circumcised boys in all of these studies \[[@b18-krcp-38-441],[@b22-krcp-38-441],[@b23-krcp-38-441],[@b46-krcp-38-441]--[@b50-krcp-38-441]\]. Thus, the results obtained from these clinical studies should not be generalized to the normal population across different geographic locations.

[Table 2](#t2-krcp-38-441){ref-type="table"} summarizes outcomes of these clinical studies. Studies conducted from 2006 to 2008 did not reveal any efficacy of CAP for preventing recurrent UTI in children with or without low-grade VUR \[[@b18-krcp-38-441],[@b22-krcp-38-441],[@b23-krcp-38-441],[@b46-krcp-38-441]--[@b50-krcp-38-441]\]. The study conducted by Roussey-Kesler et al \[[@b49-krcp-38-441]\] indicated some benefit of CAP in preventing recurrent UTI. Their study was limited to a specific population of boys who were 1 month to 3 years old and had grade III VUR. It is important to note that these studies involve certain limitations related to study design. These limitations include small sample size, absence of any placebo or active control arm, inconsistent methodology for sample collection, inclusion of children without VUR, and not using blinding to prevent bias. These studies also did not discriminate febrile UTIs from nonfebrile UTIs \[[@b23-krcp-38-441],[@b47-krcp-38-441]--[@b49-krcp-38-441]\]. The next two studies carried out by Craig et al \[[@b22-krcp-38-441]\] (Prevention of Recurrent Urinary Tract Infection in Children with Vesicoureteric Reflux and Normal Renal Tracts, PRIVENT) and Brandström et al \[[@b46-krcp-38-441]\] (Swedish reflux trial) included a placebo arm and an active control arm, respectively, to remove limitations of the study design to some extent. Results from the PRIVENT study revealed moderate efficacy of CAP for prevention of UTIs in predisposed children under 18 years (13% versus 19%, *P* value = 0.02; hazard ratio \[HR\], 0.61; 95% CI, 0.40--0.93), and the results were consistent among all subgroups studied. Results obtained from the Swedish reflux trial revealed the efficacy of CAP for preventing UTIs only in girls with VUR grade III or IV and less than 2 years of age (19% versus 57%, *P* value = 0.0002). The PRIVENT trial overcome many shortcomings related to study design and sample collection methodology as it included a placebo arm, employed blinded treatment, and involved a standardized sample collection method for diagnosis of UTIs. However, limitations of the PRIVENT trial were that it assumed UTIs did not occur in patients who did not have follow up. It did not consider compliance to CAP treatment and did not report the relationship between recurrence and concurrent VUR. It was estimated that to prevent one UTI, around 1 year of CAP treatment should be prescribed to 14 children \[[@b22-krcp-38-441]\].

Considering all aspects discussed above, the precise benefit of CAP for preventing UTIs in high-risk children remained controversial. This led to the Randomized Intervention for Children with Vesicoureteral Reflux (RIV-UR) trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which was designed to remove all limitations of the previous clinical studies. A total of 607 children with VUR who were confirmed to have their first or second febrile or symptomatic UTI were enrolled at 19 sites across the United States and were randomized to receive either CAP or matching placebo for 2 years. Results obtained from the RIVUR trial revealed that CAP reduced the risk of febrile or symptomatic recurrent UTI by 50% compared to placebo (13% versus 24%; HR, 0.50; 95% CI, 0.34--0.74). The efficacy of CAP increased progressively with time between the two groups. It was estimated that to prevent one febrile or symptomatic UTI, around 8 children would have to be treated with CAP for two years. Subgroup analysis of the RIVUR data revealed that CAP was most effective for preventing febrile or symptomatic UTIs in children who had concurrent bladder and bowel dysfunction (BBD) (HR, 0.21; 95% CI, 0.08--0.58) compared to those without concurrent BBD (HR, 1.40; 95% CI, 0.43--4.58) and in children with first febrile UTI (HR, 0.41; 95% CI, 0.26--0.64) compared to first nonfebrile UTI (HR, 1.28; 95% CI, 0.47--3.46) \[[@b50-krcp-38-441]\]. The results of the RIVUR trials were reanalyzed by another group of researchers via a risk classification system \[[@b51-krcp-38-441]\]. The high-risk groups consisted of uncircumcised boys with VUR, children with concurrent VUR and BBD, and children with Grade IV VUR. The efficacy of CAP was more pronounced in children at high risk of developing recurrent febrile or symptomatic UTI compared with children at low risk of developing recurrent febrile or symptomatic UTI. This reanalysis estimated that to prevent one febrile or symptomatic UTI, around 5 children in the high-risk group (compared with 18 children in the low-risk group) have to be treated with CAP for 2 years \[[@b51-krcp-38-441]\]. Hence, results obtained from the RIVUR trial can be utilized to identify children at high risk of developing recurrent febrile UTIs who will most benefit from CAP. This may help to avoid unnecessary antibiotic exposure to other children and reduce the emergence of antibiotic-resistant infections.

Though the RIVUR trial was successful in removing various limitations associated with previous RCTs, it also involved certain limitations. The most important limitation of the RIVUR trial was a skewed study population. About 92% of the RIVUR study population was girls, most (80.4%) included children had low-grade (II to III) VUR, and the majority of them (91.3%) had only one incidence of febrile UTI. Another limitation was the high adherence rate to study treatment owing to stringent follow-up compared with the real-world setting. In the RIVUR trial, around 77% of children received study treatment at least 75% of the time, and about 85% of children received study treatment at least 50% of the time \[[@b50-krcp-38-441]\]. However, another study that reviewed compliance in a similar population receiving a similar treatment reported a compliance rate of merely 40% \[[@b52-krcp-38-441]\]. These results raise concerns that the efficacy of CAP observed in RIVUR may not translate to the real world setting due to low adherence. Results obtained in another clinical study in India with a similar protocol to that of RIVUR produced opposite results for the efficacy of CAP compared with placebo in preventing recurrent UTIs (21.3% versus 6.5%, *P* value = 0.02; HR, 3.9; 95% CI, 1--14) \[[@b18-krcp-38-441]\]. These results further raise concerns regarding the use of RIVUR trial results in geographically-diverse populations.

The pooled RCT results ([Fig. 2](#f2-krcp-38-441){ref-type="fig"}) reveal that CAP was associated with 27% decrease in the odds of UTI (pooled RR 0.73) \[[@b18-krcp-38-441],[@b22-krcp-38-441],[@b23-krcp-38-441],[@b46-krcp-38-441]--[@b50-krcp-38-441]\]. However, the forest plot showed significant heterogeneity between studies (I^2^=63%, *P* value = 0.008) \[[@b18-krcp-38-441],[@b22-krcp-38-441],[@b23-krcp-38-441],[@b46-krcp-38-441]--[@b50-krcp-38-441]\]. Of all included RCTs, not a single study was adequately powered to assess the effectiveness of CAP for preventing renal scarring \[[@b53-krcp-38-441]\]. Hence, we cannot conclude whether CAP is helpful in averting renal scarring in children at high risk of developing recurrent febrile UTIs.

Systematic reviews and meta-analyses
====================================

Systematic review and meta-analyses allow comparison of data among clinical studies with similar study populations and study arms. [Table 3](#t3-krcp-38-441){ref-type="table"} summarizes various published systematic reviews and meta-analyses on the efficacy of CAP for preventing UTI in pediatric patients \[[@b17-krcp-38-441],[@b54-krcp-38-441]--[@b60-krcp-38-441]\]. As discussed above for clinical studies, systematic reviews and meta-analyses conducted until 2010 also lacked placebo-controlled or active-controlled clinical data. Therefore, these studies provided unreliable, variable results on the efficacy of CAP in preventing recurrent UTIs \[[@b54-krcp-38-441]--[@b57-krcp-38-441]\]. Most of these studies highlight the need for high-quality, large scale, placebo-controlled, double-blind clinical trials for appropriate estimation of the efficacy of CAP for preventing recurrent UTIs. In 2011, Williams and Craig \[[@b58-krcp-38-441]\] performed a systematic review including data from 12 clinical trials containing 6 studies that compared results with CAP and placebo/ no treatment. When data from all clinical studies were examined, CAP did not appear to reduce recurrent UTIs (RR, 0.75; 95% CI, 0.36--1.53); however, when data from studies with low risk of bias were included, CAP appeared to significantly reduce recurrent UTIs (RR, 0.68; 95% CI, 0.48--0.95). Also, the efficacy of CAP was similar among children with or without VUR. Pooled data from 3 studies indicated increased risk for emergence of multidrug-resistant bacteria in children who received CAP (RR, 2.4; 95% CI, 0.62--9.26) \[[@b58-krcp-38-441]\].

In 2015, two systematic reviews and meta-analyses that included data from the RIVUR trial were published \[[@b17-krcp-38-441],[@b59-krcp-38-441]\]. Inclusion of data from the large RIVUR trial shifted results towards significant efficacy of CAP compared with placebo in preventing recurring febrile UTIs (OR, 0.63; 95% CI, 0.42--0.96) in children irrespective of concurrent high grade VUR. The studies also showed increased risk of developing an antibiotic-resistant infection in children on CAP (OR, 8.75; 95% CI, 3.52--21.73) \[[@b17-krcp-38-441],[@b59-krcp-38-441]\]. Another systematic review on the efficacy of CAP for preventing renal scarring was published in 2017 \[[@b60-krcp-38-441]\]. As discussed above, the results indicated no influence of CAP for prevention of renal scarring (RR, 0.83; 95% CI, 0.55--1.26). A sub-analysis limited to children with VUR indicated similar results (RR, 0.79; 95% CI, 0.51--1.24) \[[@b60-krcp-38-441]\]. Recently, results from a systematic review and meta-analysis revealed that CAP may reduce the risk of recurrent symptomatic UTI in children who have had one or more previous UTIs, but the benefit may be small (RR, 0.75; 95% CI, 0.28--1.98). Additionally, a two-and-half-fold higher threat of developing an antibiotic-resistant infection in children receiving CAP (RR, 2.40; 95% CI, 0.62--9.26) was reported \[[@b61-krcp-38-441]\].

Antibiotic options for CAP
==========================

When indicated, CAP can be administered from 6 months to 12 months using narrow-spectrum antibiotics, such as nitrofurantoin (at a dose of 1 mg/kg/d) or TMP-SMX (at a dose of 2 mg/kg/d of TMP). These antibiotics are generally associated with fewer adverse events, less risk of developing multidrug-resistant secondary infections, do not disrupt commensal bowel flora, and are affordable \[[@b34-krcp-38-441],[@b61-krcp-38-441]\]. CAP should be stopped or changed if a resistant microorganism is identified in the urine culture of a pediatric patient, even if contamination of urine culture is suspected \[[@b34-krcp-38-441],[@b61-krcp-38-441]\]. In a pediatric patient with spina bifida and neurogenic bladder, intravesicular aminoglycoside irrigation can be utilized for both treatment and prophylaxis of UTIs, but there is no data on long-term toxicity in pediatric patients \[[@b62-krcp-38-441]\].

Other adjunct UTI management
============================

Various studies have reported that cranberry can be used as an adjunct therapy for recurrent UTIs due to the presence of proanthocyanidins, which are believed to be responsible for the antibacterial activity \[[@b63-krcp-38-441],[@b64-krcp-38-441]\]. Fructose and proanthocyanidins contained in cranberry have been shown to impede *in vitro* adhesion of *E. coli* fimbriae to urinary tract epithelial cell lines in a dosedependent manner \[[@b65-krcp-38-441],[@b66-krcp-38-441]\]. However, clinical pharmacologic studies have shown that the level of proanthocyanidins in urine samples was below the levels shown to be effective in *in vitro* studies. Thus, an alternative proposed mechanism is that proanthocyanidins promote the growth of non-virulent bacterial strains to indirectly prevent growth of the virulent bacteria commonly involved in UTIs \[[@b67-krcp-38-441]\]. Clinical studies have reported contradictory results on the benefit of cranberry in preventing UTIs. Results of a RCT indicated no difference in the number of children with recurrent UTIs who received cranberry juice compared with placebo; however, cranberry juice was reported to help limit recurrences and the amount of antibiotic used per patient. Results from another RCT indicated that cranberry juice successfully reduced the occurrence of recurrent UTIs over a year compared with placebo treatment \[[@b68-krcp-38-441],[@b69-krcp-38-441]\].

Several studies have reported that probiotics, the normal bacterial flora that usually colonize the human gut, can be used to prevent recurrent UTIs. A RCT involving treatment with probiotic *Lactobacillus acidophilus* and TMP-SMX showed that there was not much of a difference between the probiotic and TMP-SMX groups (18.3 versus 21.6) for preventing recurrent UTIs. However, results from another RCT indicated that a combination of probiotic with nitrofurantoin significantly lowered the occurrence of recurrent UTIs compared with nitrofurantoin alone \[[@b70-krcp-38-441],[@b71-krcp-38-441]\].

Results from a small clinical investigation suggested that weekly intravesical injection of hyaluronic acid (prevents bacterial adherence to inner epithelial lining of urinary tract) for 4 weeks effectively reduced the incidence of recurrent UTIs in children \[[@b72-krcp-38-441]\]. Large, well-designed RCTs are required to draw robust conclusions about the efficacy of cranberry juice, probiotics, or hyaluronic acid for preventing UTIs.

Conclusion
==========

No conclusive evidence can be drawn from available clinical data in favor of CAP for preventing renal scarring in children with first or second febrile UTI with or without VUR. Additional well designed studies may lead to different conclusions in the future. Currently available clinical data supports 'selective' use of CAP for preventing recurrent UTI or reducing the number of UTIs and subsequent renal scarring--in certain high-risk pediatric patients with anatomic abnormality of the urinary system. Efficient antibiotic stewardship and careful selection of appropriate antibiotics based on culture results, antibiotic susceptibility, and geographic location/local guidelines is vital for treating UTIs in children and reducing the emergence of multidrug-resistant infections.
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###### 

Studies analyzing uropathogen resistance rates and trends

  Study                                                 Location (time frame)   Age group, number, and design                                                                        Uropathogen rate                                                                                                Resistance rate
  ----------------------------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vazouras et al (2019) \[[@b43-krcp-38-441]\]          Greece (2010--2015)     \< 18 yr, 230 inpatient, retrospective                                                               *Escherichia coli* 79%, *Klebsiella* 7%                                                                         *E. coli*: AMP 42%, TMP-SMX 26%, NIT 2.3%; *Klebsiella*: AMC 13%, CXM 14%.
  Yoo et al (2019) \[[@b42-krcp-38-441]\]               Korea (2012--2017)      \< 15 yr, 550 children, retrospective                                                                *E. coli* 77% (ESBL+ 24%), *Klebsiella* 17%                                                                     *E. coli*: AMP 77%, AMC 34%, CTX 27%, NIT 7.7%, CIP 24%
  Erol et al (2018) \[[@b41-krcp-38-441]\]              Turkey (2009--2014)     \< 18 yr, 6,515 urine sample, retrospective                                                          *E. coli* 55%, *Proteus* 19%, *Klebsiella* 14%                                                                  *E. coli*: AMP 47%--56%, AMC 47%--89%, AMC 44%--51%, TMP-SMX 45%--56%, NIT 5.3%--15.2%; *Proteus*: AMP 56%--93%, AMC 43%--56%, TMP-SMX 36%--47%, AMC 13%--24%, NIT: 68%--78%
  Wang et al (2018) \[[@b40-krcp-38-441]\]              China (2013--2016)      1 mo--12 yr, 2,316 children, retrospective                                                           *Enterococcus* spp. 35%, *E. coli* 22%, *Klebsiella* 7%                                                         *Enterococcus* AMP 65%, *E. coli*: AMP 93%, TMP-SMX 58%, levofloxacin 39%; *Klebsiella*: AMP 99%, TMP-SMX 22%, GEN 43%
  Saperston et al (2014) \[[@b27-krcp-38-441]\]         United States (2009)    \< 18 yrs, 25,418 outpatients versus 5,560 inpatients, retrospective database analysis (195 sites)   *E. coli* 79% vs. 54%, *Enterococcus* 13% vs. 27%, *Klebsiella* 10% vs. 12%                                     *E. coli* resistance outpatients vs. inpatients: AMP 45% vs. 55%, TMP-SMX 24% vs. 30%, AMC 5% vs. 6%, CIP 5% vs. 9%, CRO \< 1% vs. 2%
  Garraffo et al (2014) \[[@b28-krcp-38-441]\]          France (2011)           \< 12 yr, 110 children, prospective (multicenter)                                                    *E. coli* 78%, *Proteus* 9%, *Enterococcus* 4%                                                                  *E. coli* resistance: 20% (AMX, TMP-SMX), \< 20% (AMC, CIP, GEN, NIT)
  Sakran et al (2015) \[[@b39-krcp-38-441]\]            Israel (2003--2009)     \< 18 yr, inpatients 456 first episode vs 106 recurrent UTIs, retrospective                          First vs recurrent *E. coli* 81% vs. 75%, *Klebsiella* 6% vs 5%, *Proteus* 4% vs. 5%, *Pseudomonas* 2% vs. 8%   All uropathogen resistance (first vs. recurrent) 20% (AMP, TMP/SMX), AMK 8% vs. 0%; GEN 3% vs. 5%, CXM 6% vs. 17%, NIT 6% vs. 19%
  Mohammad-Jafari et al (2012) \[[@b36-krcp-38-441]\]   Iran (2006--2009)       1 wk--12 yr, 1,439 urine samples, retrospective                                                      *E. coli* 60%, *Enterobacter* 17%, Other GNB (*Klebsiella*, *Proteus*, *Pseudomonas*) 21%                       *E. coli* resistance trend: AMP 77%--80%, CRO 10%--20%, GEN 6%--26%, AMK 0%--20%, Cefixime, 2%--38%, Nalidixic acid 2%--16 %, no change for CIP
  Ismaili et al (2011) \[[@b29-krcp-38-441]\]           Belgium (2006--2008)    \< 3 mo, 209 infants (inpatients), prospective                                                       *E. coli* 88%, *Klebsiella* 7%, *Enterobacter* 2%                                                               *E. coli* resistance: 20% (AMP, TMP-SMX), \< 20% (AMK, NIT, 2nd and 3rd generation cephalosporins)
  Doré-Bergeron et al (2009) \[[@b38-krcp-38-441]\]     Canada (2005--2007)     1--3 mo, 103, retrospective                                                                          *E. coli* 85%, *Klebsiella* 7%                                                                                  All strain resistance: GEN 2% (other resistance patterns not discussed)
  Al-Mardeni et al (2009) \[[@b37-krcp-38-441]\]        Jordan (2006--2007)     \< 4 yr, 529 children, outpatients                                                                   *E. coli* 85%, *Proteus* 39%, *Klebsiella* 35%, *Citrobacter* 15%                                               Multidrug-resistant *E. coli* 60%; resistance patterns of *E. coli* vs. non--*E. coli*: AMP 82% vs. 83%, TMP-SMX 72% vs. 80%, LEX 37% vs. 52%, NIT 21% vs. 71%, CRO 20% vs. 28%

AMC, amoxicillin-clavulanate; AMK, amikacin; AMP, ampicillin; CIP, ciprofloxacin; CRO, ceftriaxone; CXM, cefuroxime; ESBL, extended-spectrum beta-lactamase; GEN, gentamicin; GNB, gram-negative bacilli; LEX, cephalexin; NIT, nitrofurantoin; TMP-SMX, trimethoprim-sulfamethoxazole; UTIs, urinary tract infections.

###### 

Randomized controlled trials on antibiotic prophylaxis for preventing UTIs in children (2001--2019)

  Study                                                                  No. of children (cases versus control)   Age            VUR grade   Intervention         Placebo use   Follow-up duration (mo)   Outcome                                                                                                                                                                                                   Rate of resistant bacteria to prophylactic antibiotic, prophylaxis no prophylaxis
  ---------------------------------------------------------------------- ---------------------------------------- -------------- ----------- -------------------- ------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Garin et al (2006) \[[@b47-krcp-38-441]\]                              218 (100 vs. 118)                        3 mo--18 yr    I--III      TMP-SMX; NTF         No            12                        No difference in rates of recurrent UTI, pyelonephritis, or development of renal parenchymal scars                                                                                                        7/7 (100%), 0/1 (0%)
  Roussey-Kesler et al (2008) \[[@b49-krcp-38-441]\]                     225 (103 vs. 122)                        1--36 mo       I--III      TMP-SMX              No            18                        No difference in rates of recurrent UTI                                                                                                                                                                   13/18 (73%), 13/32 (39%)
  Montini et al (2008) \[[@b23-krcp-38-441]\]                            338 (211 vs. 127)                        2 mo--7 yr     I--III      TMP-SMX; Amox/clav   No            12                        No difference in incidence of febrile UTIs or scarring                                                                                                                                                    9/15 (60%), 1/12 (8%)
  Pennesi et al (2008) \[[@b48-krcp-38-441]\]                            100 (50 vs. 50)                          1--30 mo       II--IV      TMP-SMX              No            24                        No difference in recurrent pyelonephritis or scarring                                                                                                                                                     42/42 (100%), 0/35 (0%)
  Craig et al (2009) \[[@b22-krcp-38-441]\], PRIVENT                     576 (288 vs. 288)                        Birth--18 yr   I--V        TMP-SMX              Yes           12                        14 patient-years of antibiotics to prevent 1 UTI                                                                                                                                                          24/36 (67%), 13/52 (25%)[a](#tfn3-krcp-38-441){ref-type="table-fn"}
  Brandström et al (2011) \[[@b46-krcp-38-441]\], Swedish reflux trial   137 (69 vs. 68)                          1--2 yr        III--IV     TMP-SMX              No            24                        Subgroup analysis comparing 42 girls on prophylaxis with 43 girls on surveillance showed benefit in preventing UTI recurrence and scarring. No difference found in boys                                   8/10 (80%), 9/25 (36%)[b](#tfn4-krcp-38-441){ref-type="table-fn"}
  Hoberman et al (2014) \[[@b50-krcp-38-441]\]                           607 (302 vs. 305)                        2 mo--6 yr     I--IV       TMP-SMX              Yes           24                        16 patient-years of antibiotics to prevent 1 UTI and 22 patient years to prevent 1 febrile UTI. No difference in renal scarring despite 558/607 (92%) females and 380/607 (62%) having VUR grade 3 or 4   26/38 (68%), 17/69 (25%)[c](#tfn5-krcp-38-441){ref-type="table-fn"}
  Hari et al (2015) \[[@b18-krcp-38-441]\]                               93 (47 vs. 46)                           1--12 yr       I--IV       TMP-SMX              Yes           12                        Higher rate of UTI in prophylaxis group (21% versus 6%) and higher rate of resistant organism in prophylaxis group                                                                                        7/12 (58%), 1/5 (20%)[d](#tfn6-krcp-38-441){ref-type="table-fn"}

Amox/clav, amoxicillin-clavulanate; NTF, nitrofurantoin; RIVUR, Randomized Intervention for Children with Vesicoureteral Reflux; TMP-SMX, trimethoprim-sulfamethoxazole; UTI, urinary tract infection; VUR, vesicoureteral reflex.

*P* \< 0.001,

*P* = 0.038,

*P* \< 0.001,

*P* = 0.3.

###### 

Systematic reviews and meta-analyses on efficacy of antibiotic prophylaxis for preventing urinary tract infection in pediatric patients

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                     Number of studies (no. of subjects)   Antibiotic prophylaxis recommended?                Outcome measure        95% CI        Comments
  ----------------------------------------------------------------------------------------- ------------------------------------- -------------------------------------------------- ---------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Williams et al (2001) \[[@b54-krcp-38-441]\]                                              3 (392)                               Yes                                                RR: 0.31               0.10--1.00    Antibiotics reduced risk of recurrent UTI. Most included studies were poorly designed with biases known to overestimate true treatment effect.

  Williams et al (2006) \[[@b55-krcp-38-441]\]                                              8 (618)                               Yes                                                RR: 0.44               0.19--1.00    Antibiotics reduced risk of repeat positive urine culture.

  Mori et al (2009) \[[@b56-krcp-38-441]\]                                                  8 (677)                               No                                                 RR: 0.96               0.69--1.32    No difference in recurrence of symptomatic UTI or in incidence of new/progressive renal scarring.

  Dai et al (2010) \[[@b57-krcp-38-441]\]                                                   11 (2,046)                            No                                                 RR: 0.83               0.66--1.05    No effect on incidence of recurrent UTI.

  Williams and Craig (2011) \[[@b58-krcp-38-441]\]                                          5 (1,069)                             Yes                                                RR: 0.68               0.48--0.95    Antibiotics reduced risk of repeat symptomatic UTI but the benefit is small.

  Wang et al (2015) \[[@b17-krcp-38-441]\][a](#tfn8-krcp-38-441){ref-type="table-fn"}       8 (1,594)                             Yes (for recurrent UTI, not for renal scarring)    OR: 0.63               0.42--0.96    Increase antibiotic resistant uropathogens, OR: 8.75. No reduction in renal scarring.

  de Bessa et al (2015) \[[@b59-krcp-38-441]\][a](#tfn8-krcp-38-441){ref-type="table-fn"}   7 (1,593)                             Without RIVUR study: yes, only for VUR grade 3,4   RR: 0.75 (VUR 3, 4)\   0.56--1.01\   
                                                                                                                                                                                     RR: 0.87 (VUR 1, 2)    0.42--1.82    

  With RIVUR study: yes, for all VUR grades                                                 RR: 0.72 (VUR 3, 4)\                  0.56--0.92\                                                                             
                                                                                            RR: 0.51 (VUR 1, 2)                   0.32--0.79                                                                              

  Hewitt et al (2017) \[[@b60-krcp-38-441]\][a](#tfn8-krcp-38-441){ref-type="table-fn"}     7 (1,427)                             No                                                 RR: 0.83               0.55--1.26    No influence of antibiotic prophylaxis in preventing renal scarring (including those with VUR)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RIVUR, Randomized Intervention for Children with Vesicoureteral Reflux; RR, relative risk; UTI, urinary tract infection; VUR, vesicoureteral reflex.

Denote that RIVUR trial was included in their analysis.

[^1]: Edited by Eun Hui Bae, Chonnam National University, Gwangju, Republic of Korea
